Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	26.5	61.64	9.74	15.56
Short-Term Investments	124.76	12.02	0.25	0.55
Cash & Short-Term Investments	151.26	73.66	9.99	16.11
Cash Growth	1414.27%	637.44%	-37.98%	-
Prepaid Expenses	3.29	0.31	0.25	0.32
Other Current Assets	-	0.16	0.13	0.07
Total Current Assets	154.55	74.14	10.37	16.49
Property, Plant & Equipment	0.63	0.74	0.16	0.25
Other Long-Term Assets	1.84	2.64	0.01	0.01
Total Assets	157.03	77.51	10.54	16.76
Accounts Payable	2.56	2.3	1.04	0.26
Accrued Expenses	3.03	2.29	0.24	0.24
Current Portion of Leases	0.39	0.34	0.11	0.1
Total Current Liabilities	5.98	4.93	1.38	0.6
Long-Term Leases	0.34	0.44	0.05	0.16
Other Long-Term Liabilities	0.02	0.03	0	0.02
Total Liabilities	6.34	5.39	1.43	0.78
Additional Paid-In Capital	218.28	3.68	2.94	2.61
Retained Earnings	-67.64	-58.33	-37.74	-30.53
Total Common Equity	150.69	-54.64	-34.8	-27.92
Shareholders' Equity	150.69	72.11	9.1	15.98
Total Liabilities & Equity	157.03	77.51	10.54	16.76
Total Debt	0.73	0.78	0.16	0.26
Net Cash (Debt)	150.53	72.88	9.83	15.84
Net Cash Growth	1431.84%	641.67%	-37.97%	-
Net Cash Per Share	23.88	18.24	2.48	4.07
Filing Date Shares Outstanding	21.7	21.7	3.97	3.89
Total Common Shares Outstanding	21.7	4.07	3.97	3.89
Working Capital	148.58	69.21	8.99	15.9
Book Value Per Share	6.95	-13.44	-8.77	-7.18
Tangible Book Value	150.69	-54.64	-34.8	-27.92
Tangible Book Value Per Share	6.95	-13.44	-8.77	-7.18

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q